Refining mUltiple Artificial intelliGence strateGies for Automatic Pain Assessment Investigations: RUGGI Study
Launched by VALENTINA CERRONE · Jun 17, 2025
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying new ways to use artificial intelligence (AI) to automatically assess chronic pain, which includes long-lasting pain from conditions like cancer, nerve damage, or other ongoing health problems. The goal is to create computer models that can recognize and measure pain by looking at different types of information, such as brain activity, heart rate, skin responses, and facial expressions. This could help doctors better understand and manage pain without relying only on patient descriptions.
Adults who have had chronic pain for more than three months—whether from conditions like fibromyalgia, arthritis, or cancer-related pain—may be eligible to join. Participants will take part in several non-invasive tests, including wearing sensors and answering questionnaires about their pain and quality of life. These procedures are safe and designed to collect detailed information to improve AI tools for pain assessment. The study is open to all adults who can give informed consent and do not have certain psychiatric conditions or substance abuse issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults (≥18 years old) with chronic pain, defined according to IASP and ICD-11 as pain that persists or recurs for more than three months.
- * Diagnosed with either:
- • Chronic primary pain (e.g., fibromyalgia, irritable bowel syndrome, chronic headaches)
- • Chronic secondary non-cancer pain (e.g., low back pain, osteoarthritis, post-surgical pain)
- • Chronic cancer-related pain (due to cancer or its treatment)
- • Ability to understand the study procedures and provide written informed consent.
- Exclusion Criteria:
- • Current treatment with psychotropic drugs or presence of active psychiatric disorders (e.g., psychosis, major depression).
- • Known history of alcohol or substance abuse.
- • Pregnancy or breastfeeding.
- • Age under 18 years.
- • Inability to provide informed consent (e.g., due to cognitive impairment).
About Valentina Cerrone
Valentina Cerrone is a clinical trial sponsor dedicated to advancing medical research through the support and management of innovative clinical studies. With a focus on ensuring rigorous scientific standards and patient safety, Valentina Cerrone collaborates closely with research teams to facilitate the development of new therapies and improve healthcare outcomes. Their commitment to ethical practices and regulatory compliance underscores their role in driving progress within the clinical research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Salerno, , Italy
Patients applied
Trial Officials
Marco Cascella, MD, PhD
Principal Investigator
University of Salerno
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported